The DOI matches its Crossref record.
Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study
Abstract
Context: Information on the use of oral bisphosphonate agents to treat pediatric osteogenesis imperfecta (OI) is limited. Objective: The objective of the investigation was to study the efficacy and safety of daily oral alendronate (ALN) in children with OI. Design and Participants: We conducted a multicenter, double-blind, randomized, placebo-controlled study. One hundred thirty-nine children (aged 4–19 yr) with type I, III, or IV OI were randomized to either placebo (n = 30) or ALN (n = 109) for 2 yr. ALN doses were 5 mg/d in children less than 40 kg and 10 mg/d for those 40 kg and greater. Main Outcome Measures: Spine areal bone mineral density (BMD) z-score, urinary N-telopeptide of collagen type I, extremity fracture incidence, vertebral area, iliac cortical width, bone pain, physical activity, and safety parameters were measured. Results: ALN increased spine areal BMD by 51% vs. a 12% increase with placebo (P < 0.001); the mean spine areal BMD z-score increased significantly from −4.6 to −3.3 (P < 0.001) with ALN, whereas the change in the placebo group (from −4.6 to −4.5) was insignificant. Urinary N-telopeptide of collagen type I decreased by 62% in the ALN-treated group, compared with 32% with placebo (P < 0.001). Long-bone fracture incidence, average midline vertebral height, iliac cortical width, bone pain, and physical activity were similar between groups. The incidences of clinical and laboratory adverse experiences were also similar between the treatment and placebo groups. Conclusions: Oral ALN for 2 yr in pediatric patients with OI significantly decreased bone turnover and increased spine areal BMD but was not associated with improved fracture outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Marini, J. C., Forlino, A., Bächinger, H. P., Bishop, N. J., Byers, P. H., Paepe, A. D., Fassier, F., Fratzl-Zelman, N., Kozloff, K. M., Krakow, D., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.52 · Cited by 842
New perspectives on osteogenesis imperfecta
Forlino, A., Cabral, W. A., Barnes, A. M., & Marini, J. C. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.81 · Cited by 727
Optimizing Bone Health in Children and Adolescents
Golden, N. H., Abrams, S. A., COMMITTEE ON NUTRITION, Daniels, S. R., Abrams, S. A., Corkins, M. R., de Ferranti, S. D., Golden, N. H., Magge, S. N., & Schwarzenberg, S. J. (2014) · PEDIATRICS · doi:10.1542/peds.2014-2173 · Cited by 497
Bisphosphonate therapy for osteogenesis imperfecta
Dwan, K., Phillipi, C. A., Steiner, R. D., & Basel, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005088.pub4 · Cited by 405
Self-citationSclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Metadata
- Authors
- Ward, L. M., Rauch, F., Whyte, M. P., D'Astous, J., Gates, P. E., Grogan, D., Lester, E. L., McCall, R. E., Pressly, T. A., Sanders, J. O., Smith, P. A., Steiner, R. D., Sullivan, E., Tyerman, G., Smith-Wright, D. L., Verbruggen, N., Heyden, N., Lombardi, A., & Glorieux, F. H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02-01
- Volume
- 96
- Issue
- 2
- Pages
- 355-364
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2030736429
- Cited by
- 221
- References
- 0
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study. https://app.cochat.ai/papers/10.1210/jc.2010-0636
- The paper
- Ward, L. M., Rauch, F., Whyte, M. P., D'Astous, J., Gates, P. E., Grogan, D., Lester, E. L., McCall, R. E., Pressly, T. A., Sanders, J. O., Smith, P. A., Steiner, R. D., Sullivan, E., Tyerman, G., Smith-Wright, D. L., Verbruggen, N., Heyden, N., Lombardi, A., & Glorieux, F. H. (2011). Alendronate for the Treatment of Pediatric Osteogenesis Imperfecta: A Randomized Placebo-Controlled Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-0636
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.